NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
Clinical Trials
20 trialsNCT04762875 2024-11-06
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
Phase 2 Terminated
NCT04177810 2024-02-23
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01696461 2023-09-14
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
Phase 2 Completed
NCT01746173 2023-01-30
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04552743 2022-09-10
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
Stanford University
Phase 2 Completed
NCT02703779 2021-06-18
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
University of Kansas Medical Center
Phase 2 Completed
NCT01547806 2018-03-07
Collection of Transplant Stem Cells for Plasma Cell Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01097057 2018-01-23
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02098109 2017-07-18
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT01158118 2017-06-05
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
Phase 2 Completed
NCT01621477 2017-02-20
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00998049 2015-05-14
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Mayo Clinic
Phase 2 Completed
NCT00395967 2015-05-01
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
Sanofi
Phase 2 Terminated
NCT00901225 2014-05-07
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Duke University
Phase 2 Completed
NCT00322387 2014-03-13
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Sanofi
Phase 2 Completed
NCT00322491 2014-03-13
Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Sanofi
Phase 2 Completed
NCT00322842 2014-03-13
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Sanofi
Phase 2 Completed
NCT00396201 2014-03-13
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
Sanofi
Phase 2 Completed
NCT00396383 2014-03-13
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
Sanofi
Phase 2 Terminated